Loading
Humacyte, Inc. Stock: price and insider trades · United States
1 insider bought €26k of shares over the last 90 days, the latest by Jones Keith Anthony, filed 15 Sept 2026.
Humacyte, Inc.: what insiders have been doing
Humacyte, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (23 October 2025 to 23 October 2026), 5 filings came from 3 insiders.
Only purchases show up on the open market, 3 purchases in all worth €26k, filed by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Jones Keith Anthony filed the largest purchase, €15k, on 19 August 2026. The buyers include 1 senior executive.
The clock since the last published purchase (15 September 2026) now reads 39 days. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 5 filings, this issuer sits below that mark. The full history, which starts in 2020, counts 35 purchases against 58 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 2.0 m USD and net income of -40.8 m USD.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
160
Thresholds
n/a
Buy Volume
€40M
35 ops. · all time
Sell Volume
€89M
58 ops. · all time
Who traded when
BuySaleBrady W. Dougan1 buy6 sales
Laura E. Niklason4 sales
Keith Anthony Jones3 buys
Michael T. Constantino2 buys
Charles Bruce Green1 buy
Dale A. Sander1 buy
+3 other insiders
Since the insiders bought
- -27.5%Entry US$0.57 · Close 22 Oct 2026 US$0.41
- -55.9%Entry US$1.55 · Close at T+365 US$0.68
- -52.2%Entry US$1.54 · Close at T+365 US$0.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Humacyte, Inc. Buy (bullish), based on 6 analysts. Average price target: US$1.63.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.41
Analyst consensus
6 analystsBuy
US$0.50Target US$1.63(+295%)US$4.00
Income statement
RevenueUS$2M
Gross profit-US$7.7M-376% margin
EBITDA-US$22.2M-1091% margin
Net income-US$40.8M-2003.6% margin
Valuation
PER (forward)-1.7x
P/Book3.6x
Beta2.44
Balance sheet & cash
Market capUS$114.2M
Total debtUS$64.8M
Free Cash Flow-US$105.9M
Debt / Equity214%
Profitability & ownership
ROE-547.9%
ROA-49.9%
% insiders5.7%
% institutions26.8%
Last declaration on 15 September 2026
Declarations160 total
10,000 shares@ US$0.5620.0046% mcap18.5% of flowCommon StockSEC:0001193125-26-391889:0
Canonical exit: 13 Dec 2026 (T+90)
10,000 shares@ US$0.69322.7% of flowCommon StockSEC:0001193125-26-361081:0
Canonical exit: 18 Nov 2026 (T+90)
30,000 shares@ US$0.59458.8% of flowCommon StockSEC:0001193125-26-356847:0
Canonical exit: 15 Nov 2026 (T+90)
311,100 shares0Common StockSEC:0001628280-25-052723:0
311,100 shares0Common StockSEC:0001628280-25-052720:0
1,100,000 shares@ US$1.633.2% of flowCommon StockSEC:0001104659-25-081008:1
591,685 shares@ US$1.581.7% of flowCommon StockSEC:0001104659-25-081008:2
1,100,000 shares@ US$1.635.7% of flowCommon StockSEC:0001104659-25-081009:1
591,685 shares@ US$1.583.0% of flowCommon StockSEC:0001104659-25-081009:2
549,360 shares@ US$1.831.8% of flowCommon StockSEC:0001104659-25-081009:0
549,360 shares@ US$1.831.8% of flowCommon StockSEC:0001104659-25-081008:0
6,493 shares@ US$1.5412.6% of flowCommon StockSEC:0001818382-25-000052:0
Canonical exit: 13 Jul 2025 (T+90)
20,000 shares@ US$1.5321.6% of flowCommon StockSEC:0001818382-25-000050:0
Canonical exit: 9 Jul 2025 (T+90)
7,500 shares@ US$1.55100.0% of flowCommon StockSEC:0001818382-25-000049:0
Canonical exit: 9 Jul 2025 (T+90)
6,000 shares@ US$1.2944.1% of flowCommon StockSEC:0001818382-25-000045:0
Canonical exit: 7 Jul 2025 (T+90)
16,000 shares@ US$1.2621.8% of flowCommon StockSEC:0001818382-25-000044:0
Canonical exit: 6 Jul 2025 (T+90)
50,000 shares@ US$1.3235.0% of flowCommon StockSEC:0001818382-25-000046:0
Canonical exit: 7 Jul 2025 (T+90)
4,600 shares@ US$4.387222.6% of flowCommon StockSEC:0001818382-24-000216:0
Canonical exit: 4 Mar 2025 (T+90)
1,797 shares@ US$4.440.0% of flowCommon StockSEC:0001818382-24-000214:0
Canonical exit: 17 Feb 2025 (T+90)
1,797 shares@ US$4.440.0% of flowCommon StockSEC:0001818382-24-000213:0
Canonical exit: 17 Feb 2025 (T+90)
427,459 shares@ US$4.343.7% of flowCommon StockSEC:0001818382-24-000208:1
261,369 shares@ US$4.402.3% of flowCommon StockSEC:0001818382-24-000208:2
427,459 shares@ US$4.346.5% of flowCommon StockSEC:0001818382-24-000206:1
261,369 shares@ US$4.404.0% of flowCommon StockSEC:0001818382-24-000206:2
811,172 shares@ US$4.447.0% of flowCommon StockSEC:0001818382-24-000206:0
25 of 160 declarations
About Humacyte, Inc.
Humacyte, Inc. is a U.S.-based biotechnology company listed on the Nasdaq in the United States, and it is best understood as a regenerative-medicine platform rather than a single-product story. Headquartered in Durham, North Carolina, the company was founded in 2004 by Laura Niklason, a physician-scientist widely recognized for her work in tissue engineering. Its core mission is to develop universally implantable, bioengineered human tissues that can be used off the shelf, without needing tissue harvested from the patient. Humacyte’s technology is built around acellular constructs designed to become living tissue after implantation. ([investors.humacyte.com](https://investors.humacyte.com/news-releases/news-release-details/humacyte-appoints-founder-laura-niklason-md-phd-president-and/?utm_source=openai))
The company’s lead commercial focus is its ATEV, or acellular tissue engineered vessel, franchise. The flagship product, Symvess®, is positioned for extremity vascular trauma repair and is the main near-term commercial driver. Beyond trauma, Humacyte is advancing additional vascular opportunities, including arteriovenous access for hemodialysis and peripheral artery disease, while maintaining preclinical programs in coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes, and other tissue-engineering applications. In investor materials, management presents the platform as broadly applicable across multiple anatomies and disease categories. ([investors.humacyte.com](https://investors.humacyte.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Humacyte’s differentiation comes from trying to solve several persistent limitations in vascular surgery: graft availability, infection risk, and the performance constraints of conventional conduits. The company argues that its off-the-shelf, universally implantable approach could improve clinical workflow and patient outcomes, especially in urgent settings. That said, this remains a small-cap biotechnology name with meaningful execution risk. Commercial uptake, reimbursement, manufacturing scale-up, and regulatory progress are all critical to the investment case, and the company still depends on capital markets to fund development and launch activities. ([investors.humacyte.com](https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-presentation-symvessr-long-term-safety-and?utm_source=openai))
Humacyte’s operating base is in Durham, North Carolina, where its headquarters, manufacturing capabilities, and R&D functions are located in the United States. The company also has an international commercialization footprint through strategic partnerships, including a collaboration with Fresenius Medical Care for certain non-U.S. vascular rights. Recent developments in 2026 have included the commercial launch of Symvess, long-term clinical data presentations, healthcare economics analyses, acceptance of a marketing authorization application in Israel, and a registered direct financing to support commercialization and upcoming clinical milestones. These events underscore a company transitioning from development-stage biotech toward early commercialization, while still carrying high regulatory and commercial sensitivity. ([investors.humacyte.com](https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-commercial-launch-symvesstm-acellular-tissue/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
